Avalo Therapeutics (AVTX)
NASDAQ:AVTX
Want to see AVTX full AI Analyst Report?
Top Page
Avalo Therapeutics
(NASDAQ:AVTX)
Select Model
Select Model
Rating:47Neutral
Price Target:
$14.00
▼(-2.98% Downside)
Action:ReiteratedDate:04/28/26
The score is primarily held down by very weak financial performance (minimal/declining revenue, large losses, and heavy ongoing cash burn). Technicals are neutral-to-bearish with negative MACD and price below key short/intermediate moving averages. A positive offset is the cleaner balance sheet (little-to-no debt) and a recent corporate action that improves flexibility around milestone cash outflows, but these do not fully counter the core profitability and cash-flow risks.
Positive Factors
Improved Balance Sheet / Low Debt
Elimination of debt and positive equity provide durable financial flexibility for a clinical-stage biotech. With low leverage the company can fund near-term development via equity or partnerships with less bankruptcy risk, improving negotiating power on collaborations and milestone terms.
Negative Factors
High Cash Burn / Negative Free Cash Flow
Sustained negative operating and free cash flow of ~-$51M annually is a structural weakness for a non-revenue biotech. Continued burn forces reliance on external financing or partnerships, diluting existing shareholders or narrowing strategic options if capital markets tighten over the next 2–6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Balance Sheet / Low Debt
Elimination of debt and positive equity provide durable financial flexibility for a clinical-stage biotech. With low leverage the company can fund near-term development via equity or partnerships with less bankruptcy risk, improving negotiating power on collaborations and milestone terms.
Read all positive factors
Avalo Therapeutics (AVTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$366.25M
Dividend YieldN/A
Average Volume (3M)816.27K
Price to Earnings (P/E)―
Beta (1Y)0.79
Revenue Growth-86.62%
EPS Growth95.62%
CountryUS
Employees23
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.10
Shares Outstanding26,714,336
10 Day Avg. Volume826,525
30 Day Avg. Volume816,270
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)2.93
Price to Sales (P/S)4125.96
P/FCF Ratio-4.73
Enterprise Value/Market Cap0.39
Enterprise Value/Revenue2.41K
Enterprise Value/Gross Profit3.31K
Enterprise Value/Ebitda-1.69
Forecast
1Y Price Target
$42.44Price Target Upside194.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-4.27
Revenue Forecast (FY)N/A
Avalo Therapeutics Business Overview & Revenue Model
Company Description
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-...
How the Company Makes Money
As a clinical-stage biotech, Avalo Therapeutics has historically not relied on recurring product sales; detailed, current revenue composition from commercial products is null. In general, companies at this stage fund operations primarily through c...
Avalo Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 59.00K | 441.00K | 1.92M | 18.05M | 5.40M |
| Gross Profit | -285.00K | 807.00K | 640.00K | 14.62M | 3.91M |
| EBITDA | -72.92M | -68.34M | -23.29M | -37.27M | -80.48M |
| Net Income | -78.26M | -35.13M | -31.54M | -41.66M | -84.38M |
Balance Sheet | |||||
| Total Assets | 116.46M | 150.73M | 20.99M | 33.37M | 80.21M |
| Cash, Cash Equivalents and Short-Term Investments | 98.34M | 134.55M | 7.42M | 13.17M | 54.59M |
| Total Debt | 2.43M | 568.00K | 537.00K | 19.95M | 33.32M |
| Total Liabilities | 33.41M | 17.70M | 13.69M | 44.28M | 57.13M |
| Stockholders Equity | 83.05M | 133.03M | 7.30M | -10.91M | 23.08M |
Cash Flow | |||||
| Free Cash Flow | -51.46M | -49.06M | -30.84M | -26.85M | -71.00M |
| Operating Cash Flow | -51.46M | -49.06M | -30.68M | -26.75M | -70.89M |
| Investing Cash Flow | -81.72M | 356.00K | -133.00K | -95.00K | -113.00K |
| Financing Cash Flow | 14.59M | 175.85M | 25.04M | -14.70M | 106.76M |
Avalo Therapeutics Technical Analysis
Positive
14.43
Price Trends
15.32
Negative
16.29
Negative
13.79
Positive
Market Momentum
-0.41
Positive
47.41
Neutral
21.37
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVTX, the sentiment is Positive. The current price of 14.43 is below the 20-day moving average (MA) of 14.47, below the 50-day MA of 15.32, and above the 200-day MA of 13.79, indicating a neutral trend. The MACD of -0.41 indicates Positive momentum. The RSI at 47.41 is Neutral, neither overbought nor oversold. The STOCH value of 21.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AVTX.
Avalo Therapeutics Risk Analysis
Avalo Therapeutics disclosed 64 risk factors in its most recent earnings report. Avalo Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Avalo Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $182.69M | -1.32 | -65.76% | ― | ― | -63.15% | |
53 Neutral | $110.94M | -1.18 | 9999.00% | ― | -100.00% | -40.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $220.04M | -2.69 | -656.82% | ― | ― | -10.20% | |
50 Neutral | $201.08M | -3.95 | -977.67% | ― | ― | 42.43% | |
48 Neutral | $552.40M | -40.48 | -110.72% | ― | ― | 68.18% | |
47 Neutral | $366.25M | -3.11 | -77.91% | ― | -86.62% | 95.62% |
* Healthcare Sector Average
AVTX
Avalo Therapeutics
13.78
8.76
174.50%
CRBP
Corbus Pharmaceuticals
10.52
3.10
41.78%
FBRX
Forte Biosciences
28.51
21.85
328.08%
MIST
Milestone Pharmaceuticals
1.90
0.57
42.48%
ELTX
Elicio Therapeutics
10.77
5.36
99.08%
GUTS
Fractyl Health, Inc.
0.73
-0.90
-55.40%
Avalo Therapeutics Corporate Events
Business Operations and Strategy
Avalo Therapeutics Restructures AlmataBio Milestone Payment Obligations
Positive
Apr 28, 2026
On April 26, 2026, Avalo Therapeutics entered into a Milestone Buyout Option and Amendment Agreement tied to its March 2024 acquisition of AlmataBio, Inc. The deal restructures a previously agreed $15 million contingent milestone payment that was ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.